-HERV-K (HML-2) expression has been observed in melanoma cells, and HERV-K-specific CD8+ T-cell responses have shown specificity to HERV-epitope-presenting tumor cells [119].-The HERV-K env protein is a potential therapeutic target. Here, CD8A is linked to neoplasm.